HBV phenotype drug resistance detection kit and preparation method thereof

A detection kit and drug resistance technology, applied in the preparation of HBV phenotypic drug resistance detection kits, in the field of phenotypic drug resistance detection kits, to achieve the effect of high sensitivity and easy operation

Active Publication Date: 2017-12-26
盛世菁华(北京)生物科技有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The first technical problem to be solved by the present invention is to provide a kind of phenotypic drug resistance detection kit for HBV and various existing NAs drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HBV phenotype drug resistance detection kit and preparation method thereof
  • HBV phenotype drug resistance detection kit and preparation method thereof
  • HBV phenotype drug resistance detection kit and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1HB

[0044] The construction of embodiment 1HBV phenotype drug-resistant carrier

[0045] The construction steps of the HBV phenotypic drug resistance vector include producing a set of Gateway-based TM Recombinant expression vector system. The system includes a dual expression vector with secreted alkaline phosphatase and a recombinant entry vector that can replace HBV1.0 fragments. The main technical routes are as follows: Figure 8 shown.

[0046] Specific steps are as follows:

[0047] 1. Construction of pcDNA6.2-HBV1.1-sapI vector that can replace HBV1.0 fragment

[0048] The steps are specifically:

[0049] 1.1 First, amplify the multiple cloning site region of the pMD18T self-ligating vector, and the primers are as follows;

[0050] 6.2-salI-s: 5'-ACGCGTCGACCGAAAGGGGGATGTG-3' (shown in SEQ ID No.8);

[0051] 6.2-salI-as: 5'-ACGCTCGAGGAGCTCGGTACCCGG-3' (shown in SEQ ID No.9);

[0052] Use the pMD18T self-ligating carrier stored in our laboratory as a template for amplif...

Embodiment 2HB

[0071] Example 2 HBV drug resistance carrier system drug resistance detection application verification

[0072] 1. Substitution of the HBV1.0 fragment to be tested was introduced into the pcDNA6.2-HBV1.1-sapI vector constructed in Application Example 1 to form the entry clone pcDNA6.2-HBV1.1(p);

[0073] 1.1 Amplification of standard HBV C1 subtype HBV1.0 fragment

[0074] Primers used: HBV1.0-as: TAGTGGAAGCTTGACCATGGTGAGCAAGGGCGAG (shown in SEQ ID No.16);

[0075] HBV1.0-s: GCTTGGGATCCAATTCTTACTTGTACAGCTCG (shown in SEQ ID No.17);

[0076] Preserve the HBV C2 subtype plasmid template in the laboratory, reaction conditions: 94 degrees for 2 minutes; 94 degrees for 15 seconds, 55 degrees for 30 seconds, 72 degrees for 3 minutes and 20 seconds for 30 cycles of amplification; 72 degrees for 10 minutes;

[0077] 1.2 The amplified product and the pcDNA6.2-HBV1.1-sapI vector were digested with sapI and SalI and ligated to form pcDNA6.2-HBV1.1(p).

[0078] 2. Recombination: clonin...

Embodiment 3

[0085] Embodiment 3 Description about the kit

[0086] In the kit provided by the present invention, other components or structures such as primers, probes, chromogenic reagents and the like are also included. The specific instructions are as follows:

[0087] pcDNA6.2-HBV1.1-sapI vector 1 μg

[0088] pcDNA5AP-attR vector 1 μg

[0089] Primer HBV1.0-as TAGTGGAAGCTTGACCATGGTGAGCAAGGGCGAG (shown in SEQ ID No.16)

[0090] Primer HBV1.0-s GCTTGGGATCCAATTCTTACTTGTACAGCTCG (shown in SEQ ID No.17)

[0091] Other components of the kit, such as reagents for amplification PCR, etc., can be synthesized and purchased by themselves, and will not be described in detail here.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a HBV phenotype drug resistance detection kit, which includes a recombination entry vector pcDNA6.2-HBV1.1-sapI vector capable of replacing HBV1.0 fragments, and its base sequence is as shown in SEQ ID No.4 Shown, and the dual expression vector pcDNA5AP-attR vector with secretory alkaline phosphatase, its base sequence is shown in SEQ ID No.6. The drug resistance detection kit provided by the present invention mainly includes a set of expression vector system based on GatewayTM recombination. This recombination system avoids the restriction of restriction endonuclease sites on cloning, and can quickly and correctly introduce the target fragment into the expression vector. In addition, the medium supernatant can be used for chemiluminescent quantitative detection, which not only has high sensitivity, but also can be quantified and calibrated according to the standard alkaline phosphatase control, and the operation is simple and stable.

Description

technical field [0001] The invention relates to a drug resistance detection kit, in particular to a phenotypic drug resistance detection kit for HBV (hepatitis B virus) targeting various existing NAs drugs. At the same time, the invention also relates to the preparation method of the HBV phenotype drug resistance detection kit. Background technique [0002] Chronic hepatitis B (CHB) is an important medical and public health problem worldwide, currently affecting approximately 400 million people worldwide. Complications such as cirrhosis, decompensated liver disease, and hepatocellular carcinoma (HCC) may occur in up to 40% of CHB. [0003] Currently, drugs available for the treatment of chronic hepatitis B (CHB) include immunomodulators (such as interferon-α) and oral nucleoside / nucleotide analogs (NAs), including lamivudine, lamivudine, Telbivudine, Entecavir, and Tenofovir. Oral NAs have become the mainstay of chronic hepatitis B treatment due to their strong viral supp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/70C12Q1/68C12N15/85C12N15/66C12R1/93
Inventor 陈德喜乔录新魏飞力张玉林刘道洁刘秀红李庆丁渭徐树莹宋凤丽李宁
Owner 盛世菁华(北京)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap